CTI BioPharma Corp. (CTIC) Research

CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.

Market snapshot

Symbol
CTIC
Price
$9.10
Day change
+0.06%
Market cap
$1.2B
P/E ratio
-11.46x
52-week range
4.01-9.1
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$10.40

Peer companies

  • Crescent Biopharma, Inc. (CBIO)
  • CinCor Pharma, Inc. (CINC)
  • EQRx, Inc. (EQRX)
  • Ethzilla Corp. (ETHZ)
  • Gracell Biotechnologies Inc. (GRCL)
  • POINT Biopharma Global Inc. (PNT)
  • Poseida Therapeutics, Inc. (PSTX)
  • VectivBio Holding AG (VECT)

Recent insider activity

  • BVF PARTNERS L P/IL — U-Tender (43139 shares) on 2023-06-26
  • BVF PARTNERS L P/IL — U-Tender (12 shares) on 2023-06-26
  • BVF PARTNERS L P/IL — U-Tender (17 shares) on 2023-06-26
  • BVF PARTNERS L P/IL — D-Return (80000 shares) on 2023-06-26
  • BVF PARTNERS L P/IL — D-Return (80000 shares) on 2023-06-26

Open CTI BioPharma Corp. (CTIC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.